| abemaciclib based treatment | palbociclib based treatment | ribociclib based treatment |
| abemaciclib plus aromatase inhibitor | abemaciclib plus endocrine therapy | palbociclib plus endocrine therapy | palbociclib plus letrozole | ribociclib plus letrozole |
la/mBC - HR-positive - 1st line (L1) 13 | | | | | |
la/mBC - HR positive - L1 - PIK3CA mutant 1 | | | | | |